Application of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
10.3760/cma.j.issn.1673-422X.2019.10.010
- VernacularTitle: CDK4/6抑制剂在激素受体阳性乳腺癌治疗中的应用
- Author:
Qiuping MO
1
,
2
;
Yiding CHEN
1
;
Xiaochen WANG
1
,
2
Author Information
1. Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
2. Department of Breast Surgery, Zhejiang Provincial People′s Hospital, Hangzhou 310014, China
- Publication Type:Review
- Keywords:
Breast neoplasms;
Receptors, estrogen;
Cyclin-dependent kinases;
Therapeutics
- From:
Journal of International Oncology
2019;46(10):617-619
- CountryChina
- Language:Chinese
-
Abstract:
With roles of blocking cell proliferation, cyclin-dependent protein kinase (CDK) 4/6 inhi-bitors are effective and safe complementary therapies for hormone receptor-positive breast cancer. CDK4/6 inhibitors combined with endocrine therapy significantly improve the prognosis of patients with advanced or metastatic breast cancer, especially those with endocrine resistance. Indications for CDK4/6 inhibitors are also expected to broaden into early-stage breast cancer. However, mechanisms of resistance of CDK4/6 inhibitors remain elusive.
